Clinical Trial Update: The Use of Angiotensin Receptor Blockers and the Risk of Cancer

View source ↗

Summary

A completed Boehringer Ingelheim trial investigates whether angiotensin receptor blockers are associated with cancer risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Angiotensin receptor blockers (ARB) (angiotensin II receptor blocker)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Neoplasm | Status: COMPLETED